Researchers from the College of Toronto have documented a uncommon occasion of gigantomastia—irregular and extreme breast development—following the administration of the Pfizer COVID-19 vaccine.
A 19-year-old lady, beforehand wholesome with no notable medical historical past, skilled fast breast enlargement only one week after receiving her first dose of the Pfizer COVID-19 vaccine in September 2022.
Her situation worsened following the second dose, together with her breast measurement growing dramatically from a B cup to a triple G over six months.
Social media customers have dubbed this uncommon case the “Pfizer Boob Job.”


Regardless of present process intensive medical evaluations, no hormonal abnormalities or different causes have been recognized.
Medical doctors decided that the girl’s signs aligned with pseudoangiomatous stromal hyperplasia (PASH), a uncommon situation involving idiopathic fibrous mammary tissue development.
The affiliation between PASH and vaccine administration has not been beforehand established, making this case significantly noteworthy.
In accordance with the medical journal:
This case presents a wholesome younger lady with fast bilateral breast enlargement 1 week following Pfizer COVID-19 vaccine administration. After ruling out different potential causes, she underwent bilateral discount mammoplasty, with histology revealing dense terminal duct lobular items interspersed with PASH.
The affected person believed that the vaccine brought about her breast development; nonetheless, her considerations weren’t adequately addressed by her main care physicians, resulting in distrust within the healthcare system.
After a number of specialist consultations and unsuccessful remedy trials, she underwent definitive surgical remedy. Though a temporal relationship doesn’t set up causality, dismissing affected person considerations can erode belief. Physicians ought to think about and worth affected person considerations when creating therapeutic relationships.
PASH-associated gigantomastia is uncommon, with fewer than 20 documented circumstances. Present gigantomastia classification techniques don’t account for PASH as an etiological issue and lack element on the timeline of breast development or the kind of tissue concerned. Together with these components may enhance medical decision-making and streamline administration.
Additional analysis is required to develop a complete classification system for gigantomastia that assists in remedy planning and a deepens understanding of PASH.
CONCLUSIONS
The reason for gigantomastia stays unclear. Right here, we current the case of a wholesome feminine affected person who skilled fast breast enlargement, progressing from a B cup to a triple G cup over 6 months, starting 1 week following Pfizer COVID-19 vaccination.
She underwent bilateral discount mammoplasty, sophisticated by intraoperative bleeding, necessitating postoperative transfusions. Surgical specimens confirmed PASH. Additional analysis is required to know PASH etiology, refine gigantomastia classification, and discover the potential hyperlink between the Pfizer vaccine, gigantomastia, and PASH.